imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Æxlishemjandi lyf - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
pulmicort dreifa í eimgjafa 0,125 mg/ml
astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,125 mg/ml
pulmicort dreifa í eimgjafa 0,25 mg/ml
astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,25 mg/ml
pulmicort dreifa í eimgjafa 0,5 mg/ml
astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,5 mg/ml
pulmicort turbuhaler innöndunarduft 100 míkróg/skammt
astrazeneca a/s - budesonidum inn - innöndunarduft - 100 míkróg/skammt
pulmicort turbuhaler innöndunarduft 200 míkróg/skammt
astrazeneca a/s - budesonidum inn - innöndunarduft - 200 míkróg/skammt
pulmicort turbuhaler innöndunarduft 400 míkróg/skammt
astrazeneca a/s - budesonidum inn - innöndunarduft - 400 míkróg/skammt
bricanyl turbuhaler innöndunarduft 0,5 mg/úðaskammt
astrazeneca a/s - terbutalinum súlfat - innöndunarduft - 0,5 mg/úðaskammt
bricanyl turbuhaler innöndunarduft 0,25 mg/úðaskammt
astrazeneca a/s - terbutalinum súlfat - innöndunarduft - 0,25 mg/úðaskammt
oxis turbuhaler innöndunarduft 4,5 míkrog/skammt
astrazeneca a/s - formoterolum fúmarat - innöndunarduft - 4,5 míkrog/skammt